BioNTech/Moderna are poised to income streams of billions of $ through guaranteed sales, with the very real possibility of more to come if either revaccination is necessary or there are more applications for the mRNA technology.
With that in mind, they are quite conservatively valued by the market right now.
Since the results of the regulatory tests and safety and efficacy validations can mostly be transferred for slight vaccine modifications (at least that's my state of knowledge), a variation should not have to go through the entire chain of test phases again before it can be cleared for use.
If anything, the prospect of mutations can only be seen as a significant moat for mRNA vaccine manufacturers, because their technology is the fastest when it comes to such adaptions.
Is that kinda like saying the 737-MAX wasn't really a new type of plane?